Immatics N.V. (IMTX)
|Net Income (ttm)||-242.34M|
|Trading Day||June 22|
|Day's Range||11.53 - 11.96|
|52-Week Range||8.66 - 18.42|
Tuebingen , Germany and Houston, Texas , May 26 , 2021 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirectin...
Tuebingen , Germany and Houston, TX , May 18 , 20 2 1 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting...
Tuebingen, Germany and Houston, TX, March 30, 2021 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting ca...
Investors liked the company's latest clinical update.
A press release from the company is showing promise in shrinking cancerous tumors. The discoveries are leading to a rise in IMTX stock.
Immatics Stock Trading Higher As Cell Therapy Program Shows Anti-Tumor Activities In Pretreated Cancer Patients
Immatics NV (NASDAQ: IMTX) has announced a clinical data update from the dose-escalation cohorts of the ongoing Phase 1 trial evaluating its ACTengine product candidates IMA201, IMA202, and IMA203. Data...
bluebird bio, Inc. (NASDAQ: BLUE), Onconova Therapeutics, Inc. (NASDAQ: ONTX), FSD Pharma Inc. (NASDAQ: HUGE) and Immatics N.V. (NASDAQ: IMTX) are among the biggest biopharma movers in Wednesday's session.
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct therapeutic modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients ... [Read more...]
|Stock Exchange |
|Ticker Symbol |
In 2020, Immatics's revenue was $31.25 million, an increase of 69.40% compared to the previous year's $18.45 million. Losses were -$229.06 million, 625.5% more than in 2019.
According to 5 analysts, the average rating for Immatics stock is "Strong Buy." The 12-month stock price forecast is 23.75, which is an increase of 104.74% from the latest price.